Influence of dietary combined herbs extract of Curcuma zedoaria (Christm.) Roscoe and Phyllanthus niruri L. on the immune response of DMBA-induced carcinogenesis mouse model
DOI:
https://doi.org/10.15359/ru.39-1.9Keywords:
diseases, cancer, immunosuppressive, Curcuma zedoaria, Phyllanthus niruriAbstract
[Objective] Cancer is one of the major causes of death and one of the most significant burdens on global healthcare systems and communities. Breast cancer is one of the most lethal cancers in both sexes, trailing only lung, colorectal, liver, and stomach cancer. Multiple strategies have been offered to combat the occurrence. However, effective and side-effect-free medications are still required. In this study, we aimed to evaluate the immunomodulatory effects of the dietary combined herbs extract of Curcuma zedoaria (Christm.) Roscoe and Phyllanthus niruri L. against 7,12-Dimethylbenz[α]anthrancene (DMBA)-induced carcinogenesis mouse model. [Methodology] Six experimental groups were set, including a vehicle group, DMBA group, cisplatin treatment with a dose of 3 mg/kg BW, Cheral dose treatment of 1.233 mg/kg BW, 2.466 mg/kg BW, and 4.923 mg/kg BW. Flow cytometry analysis of the expression number of M2 macrophages, T helper 17 cells, regulatory T cells, and B cells was performed. [Results] Interestingly, in the present study, we found that the combination of C. zedoaria and P. niruri extract showed an ameliorative effect on DMBA-induced carcinogenesis mouse model by suppressing several immune cells, including M2 macrophages, T helper 17 cells, regulatory T cells, and B cells in the secondary lymphoid organ. [Conclusion] Thus, these results suggested that combining C. zedoaria and P. niruri extracts could be used for anti-cancer drug candidate development.
Downloads
References
Abba, M. C., Zhong, Y., Lee, J., Kil, H., Lu, Y., Takata, Y., Simper, M. S., Gaddis, S., Shen, J. and Aldaz, C. M. (2016). DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. Oncotarget, 7(39), 64289-64299. https://doi.org/10.18632/oncotarget.11733
Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., Mahdian-Shakib, A., Jadidi-Niaragh, F., Azizi, G. and Baradaran, B. (2017). The paradox of Th17 cell functions in tumor immunity. Cellular Immunology, 322, 15–25. https://doi.org/10.1016/j.cellimm.2017.10.015
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Zarrin, V., Moghadam, E. R., Hashemi, F., Makvandi, P., Samarghandian, S., Khan, H., Hashemi, F., Najafi, M. and Mirzaei, H. (2020). Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.585413
Bose, S., Panda, A. K., Mukherjee, S. and Sa, G. (2015). Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Division, 10(1), 1–13.
Boye, A. (2021). A cytokine in turmoil: Transforming growth factor beta in cancer. Biomedicine & Pharmacotherapy, 139, 111657. https://doi.org/10.1016/j.biopha.2021.111657
Cendrowicz, E., Sas, Z., Bremer, E. and Rygiel, T. P. (2021). The Role of Macrophages in Cancer Development and Therapy. Cancers, 13(8), 1946. https://doi.org/10.3390/cancers13081946
Chinen, T., Kannan, A. K., Levine, A. G., Fan, X., Klein, U., Zheng, Y., Gasteiger, G., Feng, Y., Fontenot, J. D. and Rudensky, A. Y. (2016). An essential role for IL-2 receptor in regulatory T cell function. Nature Immunology, 17(11), 1322–1333. https://doi.org/10.1038/ni.3540
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R. and van der Burg, S. H. (2013). Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Research, 73(8), 2480–2492. https://doi.org/10.1158/0008-5472.CAN-12-3542
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I. and Morales-Montor, J. (2015). The Role of Cytokines in Breast Cancer Development and Progression. Journal of Interferon & Cytokine Research, 35(1), 1–16. https://doi.org/10.1089/jir.2014.0026
Fridman, W. H., Petitprez, F., Meylan, M., Chen, T. W.-W., Sun, C.-M., Roumenina, L. T. and Sautès-Fridman, C. (2021). B cells and cancer: To B or not to B? Journal of Experimental Medicine, 218(1). https://doi.org/10.1084/jem.20200851
Gao, S.-H., Liu, S.-Z., Wang, G.-Z. and Zhou, G.-B. (2021). CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. Life, 11(12), 1282. https://doi.org/10.3390/life11121282
Ge, Y., Huang, M. and Yao, Y. (2020). Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis. Frontiers in Immunology, 11, 1–13. https://doi.org/10.3389/fimmu.2020.01558
Gharge, S., Hiremath, S. I., Kagawad, P., Jivaje, K., Palled, M. S. and Suryawanshi, S. S. (2021). Curcuma zedoaria Rosc (Zingiberaceae): A review on its chemical, pharmacological and biological activities. Future Journal of Pharmaceutical Sciences, 7(1), 166. https://doi.org/10.1186/s43094-021-00316-1
Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 88, 1–20. https://doi.org/10.1016/j.bioorg.2019.102925
Ghoshdastider, U., Rohatgi, N., Mojtabavi Naeini, M., Baruah, P., Revkov, E., Guo, Y. A., Rizzetto, S., Wong, A. M. L., Solai, S., Nguyen, T. T., Yeong, J. P. S., Iqbal, J., Tan, P. H., Chowbay, B., Dasgupta, R. and Skanderup, A. J. (2021). Pan-Cancer Analysis of Ligand–Receptor Cross-talk in the Tumor Microenvironment. Cancer Research, 81(7), 1802–1812. https://doi.org/10.1158/0008-5472.CAN-20-2352
Giordano, A. and Tommonaro, G. (2019). Curcumin and Cancer. Nutrients, 11(10), 2376. https://doi.org/10.3390/nu11102376
Gun, S. Y., Lee, S. W. L., Sieow, J. L. and Wong, S. C. (2019). Targeting immune cells for cancer therapy. Redox Biology, 25. https://doi.org/10.1016/j.redox.2019.101174
Henke, E., Nandigama, R. and Ergün, S. (2020). Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences, 6, 1–24. https://doi.org/10.3389/fmolb.2019.00160
Jantan, I., Haque, M. A., Ilangkovan, M. and Arshad, L. (2019). An Insight Into the Modulatory Effects and Mechanisms of Action of Phyllanthus Species and Their Bioactive Metabolites on the Immune System. Frontiers in Pharmacology, 10, 1–19. https://doi.org/10.3389/fphar.2019.00878
Jean Baptiste, S., Le, T. H. Y., Le, T. K. V., Vu, D. N. and Nguyen, D. D. (2022). Anti-cancer Immune-modulatory Activities of Panax Genus Extracts and Bioactive Compounds. Food Reviews International, 38(7), 1461–1484. https://doi.org/10.1080/87559129.2020.1817065
Karpisheh, V., Ahmadi, M., Abbaszadeh-Goudarzi, K., Mohammadpour Saray, M., Barshidi, A., Mohammadi, H., Yousefi, M. and Jadidi-Niaragh, F. (2022). The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell International, 22(1), 108. https://doi.org/10.1186/s12935-022-02528-8
Kim, M. J., Ha, S. J., So, B. R., Kim, C.-K., Kim, K.-M. and Jung, S. K. (2021). NADPH Oxidase and Epidermal Growth Factor Receptor Are Promising Targets of Phytochemicals for Ultraviolet-Induced Skin Carcinogenesis. Antioxidants, 10(12), Article 12. https://doi.org/10.3390/antiox10121909
Kopustinskiene, D. M., Jakstas, V., Savickas, A. and Bernatoniene, J. (2020). Flavonoids as Anticancer Agents. Nutrients, 12(2), 457. https://doi.org/10.3390/nu12020457
Krstić, J., Trivanović, D., Mojsilović, S. and Santibañez, J. F. (2015). Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression. Oxidative Medicine and Cellular Longevity, 2015, 654594. https://doi.org/10.1155/2015/654594
Larigot, L., Juricek, L., Dairou, J. and Coumoul, X. (2018). AhR signaling pathways and regulatory functions. Biochimie Open, 7, 1–9. https://doi.org/10.1016/j.biopen.2018.05.001
Lee, C., Jeong, H., Lee, H., Hong, M., Park, S. and Bae, H. (2020). Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.00077
Lewis, S. M., Williams, A. and Eisenbarth, S. C. (2019). Structure and function of the immune system in the spleen. Science Immunology, 4(33), eaau6085.
Li, C., Jiang, P., Wei, S., Xu, X. and Wang, J. (2020). Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects. Molecular Cancer, 19(1), 1–23. https://doi.org/10.1186/s12943-020-01234-1
Li, Y., Jiang, M., Li, M., Chen, Y., Wei, C., Peng, L., Liu, X., Liu, Z., Tong, G., Zhou, D. and He, J. (2019). Compound Phyllanthus urinaria L Inhibits HBV-Related HCC through HBx-SHH Pathway Axis Inactivation. Evidence-Based Complementary and Alternative Medicine, 2019, 1–15. https://doi.org/10.1155/2019/1635837
Liao, H., Ye, J., Gao, L. and Liu, Y. (2021). The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. Biomedicine & Pharmacotherapy, 133, 110917. https://doi.org/10.1016/j.biopha.2020.110917
Lin, S.-R., Chang, C.-H., Hsu, C.-F., Tsai, M.-J., Cheng, H., Leong, M. K., Sung, P.-J., Chen, J.-C. and Weng, C.-F. (2020). Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. British Journal of Pharmacology, 177(6), 1409–1423. https://doi.org/10.1111/bph.14816
Lis-López, L., Bauset, C., Seco-Cervera, M. and Cosín-Roger, J. (2021). Is the Macrophage Phenotype Determinant for Fibrosis Development? Biomedicines, 9(12), Article 12. https://doi.org/10.3390/biomedicines9121747
Liu, J., Geng, X., Hou, J. and Wu, G. (2021). New insights into M1/M2 macrophages: Key modulators in cancer progression. Cancer Cell International, 21(1), 1–7. https://doi.org/10.1186/s12935-021-02089-2
Liu, Y., Guo, Q.-F., Chen, J.-L., Li, X.-R., Hou, F., Liu, X.-Y., Zhang, W.-J., Zhang, Y., Gao, F.-F., Zhang, Y.-Z., Cui, B.-X. and Liu, N.-F. (2021). Correlations between alterations of T-helper 17 cells and treatment efficacy after concurrent radiochemotherapy in locally advanced cervical cancer (stage IIB–IIIB): A 3-year prospective study. Chinese Medical Journal, 134(8), 954–962. https://doi.org/10.1097/CM9.0000000000001475
Ma, K., Yang, L., Shen, R., Kong, B., Chen, W., Liang, J., Tang, G. and Zhang, B. (2018). Th17 cells regulate the production of CXCL1 in breast cancer. International Immunopharmacology, 56, 320–329. https://doi.org/10.1016/j.intimp.2018.01.026
Mazambani, S., Morris, M. and Cheriyath, V. (2019). Epigenome modulated xenobiotic detoxification pathways control DMBA-induced breast cancer in agouti Avy/a mice. Epigenetics, 14(7), 708–720. https://doi.org/10.1080/15592294.2019.1610306
Nagarsheth, N., Wicha, M. S. and Zou, W. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews. Immunology, 17(9), 559–572. https://doi.org/10.1038/nri.2017.49
Ohue, Y. and Nishikawa, H. (2019). Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Science, 110(7), 2080–2089. https://doi.org/10.1111/cas.14069
Ozga, A. J., Chow, M. T. and Luster, A. D. (2021). Chemokines and the immune response to cancer. Immunity, 54(5), 859–874. https://doi.org/10.1016/j.immuni.2021.01.012
Pandya, P. H., Murray, M. E., Pollok, K. E. and Renbarger, J. L. (2016). The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. Journal of Immunology Research, 2016, 4273943. https://doi.org/10.1155/2016/4273943
Paul, S. and Sa, G. (2021). Curcumin as an Adjuvant to Cancer Immunotherapy. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.675923
Potteaux, S., Lehmann-Che, J., Bensussan, A., Le Naour, R. and Merrouche, Y. (2020). Multiple Roles of the Interleukin IL-17 Members in Breast Cancer and Beyond. Journal of Cellular Immunology, 2(2), Article 2. https://doi.org/10.33696/immunology.1.020
Pourhanifeh, M. H., Darvish, M., Tabatabaeian, J., Fard, M. R., Mottaghi, R., Azadchehr, M. J., Jahanshahi, M., Sahebkar, A. and Mirzaei, H. (2020). Therapeutic role of curcumin and its novel formulations in gynecological cancers. Journal of Ovarian Research, 13(1), 130. https://doi.org/10.1186/s13048-020-00731-7
Putra, W. E., Mentari, A. M. L. S., Ratnasari, D., Chairunniza, D., Hidayatullah, A. and Rifa’i, M. (2024). Immunosuppressive and ameliorative effects of dietary combined herbs extract of Curcuma zedoaria (Christm.) Roscoe and Phyllanthus niruri L. in DMBA-induced breast cancer mouse model. Fabad Journal of Pharmaceutical Sciences. 49(1), 91-110. https://doi.org/10.55262/fabadeczacilik.1329094
Raggi, F., Pelassa, S., Pierobon, D., Penco, F., Gattorno, M., Novelli, F., Eva, A., Varesio, L., Giovarelli, M. and Bosco, M. C. (2017). Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. Frontiers in Immunology, 8, 1097. https://doi.org/10.3389/fimmu.2017.01097
Rodenak-Kladniew, B., Castro, M. A., Crespo, R., Galle, M. and García de Bravo, M. (2020). Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon, 6(12), e05639. https://doi.org/10.1016/j.heliyon.2020.e05639
Roux, C., Jafari, S. M., Shinde, R., Duncan, G., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A., Palomero, L., Garcia-Valero, M., Pujana, M. A., Mak, T. W., McGaha, T. L., Cappello, P. and Gorrini, C. (2019). Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences, 116(10), 4326–4335. https://doi.org/10.1073/pnas.1819473116
Saahene, R. O., Agbo, E., Barnes, P., Yahaya, E. S., Amoani, B., Nuvor, S. V. and Okyere, P. (2021). A Review: Mechanism of Phyllanthus urinaria in Cancers—NF-κB, P13K/AKT, and MAPKs Signaling Activation. Evidence-Based Complementary and Alternative Medicine : ECAM, 2021, 4514342. https://doi.org/10.1155/2021/4514342
Saeedifar, A. M., Mosayebi, G., Ghazavi, A., Bushehri, R. H. and Ganji, A. (2021). Macrophage polarization by phytotherapy in the tumor microenvironment. Phytotherapy Research, 35(7), 3632–3648. https://doi.org/10.1002/ptr.7058
Sarvaria, A., Madrigal, J. A. and Saudemont, A. (2017). B cell regulation in cancer and anti-tumor immunity. Cellular & Molecular Immunology, 14(8), 662–674. https://doi.org/10.1038/cmi.2017.35
Sasaki-Kudoh, E., Kudo, I., Kakizaki, Y., Hosaka, M., Ikeda, S.-I., Uemura, S., Grave, E., Togashi, S., Sugawara, T., Shimizu, H. and Itoh, H. (2017). Cisplatin Inhibits AhR Activation. American Journal of Molecular Biology, 8(1), Article 1. https://doi.org/10.4236/ajmb.2018.81006
Shen, M., Wang, J. and Ren, X. (2018). New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. Frontiers in Immunology, 9, 470. https://doi.org/10.3389/fimmu.2018.00470
Siegel, R. L., Miller, K. D., Fuchs, H. E. and Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708
Sun, L., Jin, H. and Li, H. (2016). GARP: A surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing. Oncotarget, 7(27), 42826–42836. https://doi.org/10.18632/oncotarget.8753
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P. and Zhu, H.-P. (2017). Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences, 13(11), 1387–1397. https://doi.org/10.7150/ijbs.21635
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Syed, V. (2016). TGF-β Signaling in Cancer. Journal of Cellular Biochemistry, 117(6), 1279–1287. https://doi.org/10.1002/jcb.25496
Teymouri, M., Pirro, M., Fallarino, F., Gargaro, M. and Sahebkar, A. (2018). IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. International Journal of Cancer, 143(9), 2105–2115. https://doi.org/10.1002/ijc.31382
Thacker, P. C. and Karunagaran, D. (2015). Curcumin and Emodin Down-Regulate TGF-β Signaling Pathway in Human Cervical Cancer Cells. PLOS ONE, 10(3), e0120045. https://doi.org/10.1371/journal.pone.0120045
Togashi, Y., Shitara, K. and Nishikawa, H. (2019). Regulatory T cells in cancer immunosuppression—Implications for anticancer therapy. Nature Reviews Clinical Oncology, 16(6), Article 6. https://doi.org/10.1038/s41571-019-0175-7
Vitiello, G. A. and Miller, G. (2019). Targeting the interleukin-17 immune axis for cancer immunotherapy. Journal of Experimental Medicine, 217(1), e20190456. https://doi.org/10.1084/jem.20190456
Welte, T. and Zhang, X. H.-F. (2015). Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease. Mediators of Inflammation, 2015, e804347. https://doi.org/10.1155/2015/804347
Willenbacher, E., Khan, S. Z., Mujica, S. C. A., Trapani, D., Hussain, S., Wolf, D., Willenbacher, W., Spizzo, G. and Seeber, A. (2019). Curcumin: New Insights into an Ancient Ingredient against Cancer. International Journal of Molecular Sciences, 20(8), 8. https://doi.org/10.3390/ijms20081808
Wu, S., Zhu, W., Thompson, P. and Hannun, Y. A. (2018). Evaluating intrinsic and non-intrinsic cancer risk factors. Nature Communications, 9, 3490. https://doi.org/10.1038/s41467-018-05467-z
Yam-Puc, J. C., Zhang, L., Zhang, Y. and Toellner, K.-M. (2018). Role of B-cell receptors for B-cell development and antigen-induced differentiation. F1000Research, 7, 1–9. https://doi.org/10.12688/f1000research.13567.1
Yin, J., Wang, L., Wang, Y., Shen, H., Wang, X. and Wu, L. (2019). Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway. OncoTargets and Therapy, 12, 3893–3903. https://doi.org/10.2147/OTT.S199601
Yu, Y., Ke, L., Xia, W.-X., Xiang, Y., Lv, X. and Bu, J. (2019). Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma. Technology in Cancer Research & Treatment, 18, 1–11. https://doi.org/10.1177/1533033819874807
Zhang, J., Wang, X., Vikash, V., Ye, Q., Wu, D., Liu, Y. and Dong, W. (2016). ROS and ROS-Mediated Cellular Signaling. Oxidative Medicine and Cellular Longevity, 2016, 4350965. https://doi.org/10.1155/2016/4350965
Zhao, J., Chen, X., Herjan, T. and Li, X. (2020). The role of interleukin-17 in tumor development and progression. Journal of Experimental Medicine, 217(1), e20190297. https://doi.org/10.1084/jem.20190297
Zhou, D., Yang, K., Chen, L., Zhang, W., Xu, Z., Zuo, J., Jiang, H. and Luan, J. (2017). Promising landscape for regulating macrophage polarization: Epigenetic viewpoint. Oncotarget, 8(34), 57693–57706. https://doi.org/10.18632/oncotarget.17027
Zhu, Z., Zhang, H., Chen, B., Liu, X., Zhang, S., Zong, Z. and Gao, M. (2020). PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Frontiers in Immunology, 11, 1–9. https://doi.org/10.3389/fimmu.2020.588552
Ziebart, A., Huber, U., Jeske, S., Laban, S., Doescher, J., Hoffmann, T. K., Brunner, C., Jackson, E. K. and Schuler, P. J. (2017). The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma. Oncotarget, 9(5), 5834–5847. https://doi.org/10.18632/oncotarget.23533
Published
Issue
Section
License
Copyright (c) 2025 Shared by Journal and Authors (CC-BY-NC-ND)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors guarantee the journal the right to be the first publication of the work as licensed under a Creative Commons License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal https://creativecommons.org/licenses/by-nc-nd/4.0/.
2. Authors can set separate additional agreements for non-exclusive distribution of the version of the work published in the journal (eg, place it in an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. The authors have declared to hold all permissions to use the resources they provided in the paper (images, tables, among others) and assume full responsibility for damages to third parties.
4. The opinions expressed in the paper are the exclusive responsibility of the authors and do not necessarily represent the opinion of the editors or the Universidad Nacional.
Uniciencia Journal and all its productions are under Creative Commons Atribución-NoComercial-SinDerivadas 4.0 Unported.
There is neither fee for access nor Article Processing Charge (APC)
